他汀类药物有望对抗肝病进展。
Statins Show Promise Against Progression of Liver Disease.
作者信息
Francis Prashanth, Forman Lisa M
机构信息
Division of Gastroenterology and Hepatology University of Colorado Aurora CO.
出版信息
Clin Liver Dis (Hoboken). 2021 Dec 20;18(6):280-287. doi: 10.1002/cld.1143. eCollection 2021 Dec.
Abstract
Content available: Audio Recording.
摘要
内容提供
音频记录。
相似文献
1
Statins Show Promise Against Progression of Liver Disease.他汀类药物有望对抗肝病进展。
Clin Liver Dis (Hoboken). 2021 Dec 20;18(6):280-287. doi: 10.1002/cld.1143. eCollection 2021 Dec.
2
Promoting knowledge of statins in patients with low health literacy using an audio booklet.使用音频手册提高健康素养较低患者对他汀类药物的认知。
Patient Prefer Adherence. 2011;5:397-403. doi: 10.2147/PPA.S19995. Epub 2011 Aug 10.
3
Editorial: Statins and Liver Disease: Is it Time to Recommend Statins to Prevent Liver Disease Progression?社论：他汀类药物与肝脏疾病：是时候推荐使用他汀类药物来预防肝脏疾病进展了吗？
Am J Gastroenterol. 2017 Oct;112(10):1506-1507. doi: 10.1038/ajg.2017.250.
4
Statins for treatment of chronic liver disease.他汀类药物治疗慢性肝病。
Curr Opin Gastroenterol. 2021 May 1;37(3):200-207. doi: 10.1097/MOG.0000000000000716.
5
Statin Use in Patients With Chronic Liver Disease and Cirrhosis: Current Evidence and Future Directions.慢性肝病和肝硬化患者使用他汀类药物：当前证据与未来方向
Gastroenterology Res. 2022 Feb;15(1):1-12. doi: 10.14740/gr1498. Epub 2022 Feb 25.
6
The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis.他汀类药物在慢性肝病和肝硬化患者中的应用。
Curr Treat Options Gastroenterol. 2018 Jun;16(2):226-240. doi: 10.1007/s11938-018-0180-4.
7
Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis.他汀类药物对慢性肝病肝纤维化发生率、肝失代偿及死亡率的有益影响：一项系统评价与荟萃分析
Am J Gastroenterol. 2017 Oct;112(10):1495-1505. doi: 10.1038/ajg.2017.170. Epub 2017 Jun 6.
8
Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects.他汀类药物在慢性肝病和肝硬化患者中的应用：当前观点与前景
Curr Gastroenterol Rep. 2017 Sep;19(9):43. doi: 10.1007/s11894-017-0584-7.
9
Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study.他汀类药物治疗非酒精性脂肪性肝病和慢性肝酶升高：一项组织病理学随访研究
J Hepatol. 2007 Jul;47(1):135-41. doi: 10.1016/j.jhep.2007.02.013. Epub 2007 Mar 8.
10
The role of statins in amyotrophic lateral sclerosis: protective or not?他汀类药物在肌萎缩侧索硬化症中的作用：是否具有保护作用？
Front Neurosci. 2024 Jun 5;18:1422912. doi: 10.3389/fnins.2024.1422912. eCollection 2024.
引用本文的文献
1
Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches.当前治疗肝纤维化的研究：在重新利用 FDA 批准的药物和其他新兴方法之间。
J Pharm Pharm Sci. 2023 Nov 7;26:11808. doi: 10.3389/jpps.2023.11808. eCollection 2023.
2
Discovery of farnesoid X receptor and its role in bile acid metabolism.法尼酯X受体的发现及其在胆汁酸代谢中的作用。
Mol Cell Endocrinol. 2022 May 15;548:111618. doi: 10.1016/j.mce.2022.111618. Epub 2022 Mar 11.
3
Simvastatin ameliorates oxidative stress levels in HepG2 cells and hyperlipidemic rats.辛伐他汀可改善HepG2细胞和高脂血症大鼠的氧化应激水平。
Curr Res Pharmacol Drug Discov. 2022 Jan 28;3:100088. doi: 10.1016/j.crphar.2022.100088. eCollection 2022.
本文引用的文献
1
Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis.他汀类药物与乙型肝炎病毒或丙型肝炎病毒感染患者肝细胞癌风险的关系：一项荟萃分析。
BMC Gastroenterol. 2020 Apr 9;20(1):98. doi: 10.1186/s12876-020-01222-1.
2
Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis.他汀类药物的使用可降低肝细胞癌的发病率：一项更新的荟萃分析。
Cancers (Basel). 2020 Apr 3;12(4):874. doi: 10.3390/cancers12040874.
3
Managing the Symptoms and Complications of Cholestasis.胆汁淤积症状及并发症的管理
Clin Liver Dis (Hoboken). 2020 Apr 4;15(3):120-124. doi: 10.1002/cld.901. eCollection 2020 Mar.
4
Use of Statins in Patients With and Without Liver Disease.他汀类药物在有肝病和无肝病患者中的应用。
Clin Liver Dis (Hoboken). 2020 Feb 25;15(1):40-45. doi: 10.1002/cld.866. eCollection 2020 Jan.
5
Statin Use is Protective Against Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Case-control Study.他汀类药物的使用可预防非酒精性脂肪性肝病患者的肝细胞癌：一项病例对照研究。
J Clin Gastroenterol. 2020 Sep;54(8):733-740. doi: 10.1097/MCG.0000000000001260.
6
Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.他汀类药物的使用与慢性乙型肝炎患者肝细胞癌风险的关系。
Hepatology. 2020 Jun;71(6):2023-2032. doi: 10.1002/hep.30973. Epub 2020 Feb 14.
7
Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis.原发性胆汁性胆管炎患者的血脂紊乱模式和心血管风险评估。
Ann Hepatol. 2019 Nov-Dec;18(6):879-882. doi: 10.1016/j.aohep.2019.07.006. Epub 2019 Aug 22.
8
Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.脂溶性他汀类药物与慢性病毒性肝炎患者肝细胞癌和死亡风险：来自瑞典全国人群的结果。
Ann Intern Med. 2019 Sep 3;171(5):318-327. doi: 10.7326/M18-2753. Epub 2019 Aug 20.
9
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.普伐他汀联合索拉非尼不能改善晚期肝细胞癌的生存。
J Hepatol. 2019 Sep;71(3):516-522. doi: 10.1016/j.jhep.2019.04.021. Epub 2019 May 22.
10
Statin use and risk of liver cancer: Evidence from two population-based studies.他汀类药物的使用与肝癌风险：来自两项基于人群的研究证据。
Int J Cancer. 2020 Mar 1;146(5):1250-1260. doi: 10.1002/ijc.32426. Epub 2019 Jun 4.
Zotero 插件